- Business strategy and innovation
- Healthcare economics
- Industrial organization
- Intellectual property
- Market analysis and research
- Pharmaceutical economics
- Pharmaceutical pricing and reimbursement
- Public policy
- Animal health
- Medical devices
Richard Manning is an expert in providing data-driven insights to help various clients solve complex economic problems. He has significant experience conducting economic analyses in matters involving breach of contract, antitrust, patent infringement, pricing, and public policy. Dr. Manning has testified in US District Court, served as consulting expert, and prepared reports and papers on various matters in the biopharmaceutical and healthcare industries. His career includes 14 years as an executive at multinational pharmaceutical companies, where he led economic analysis and strategy development to shape practices related to emerging business concerns.
Prior to joining Bates White, Dr. Manning was an Executive Director at Merck & Co., Inc. where he oversaw economic analysis and strategy relative to challenges affecting pricing and reimbursement and intellectual property protection in worldwide markets. Previously, he was a Senior Director at Pfizer, Inc. During his 12 years with Pfizer, his team conducted economic analysis for strategic decision-making and worked with outside academic economists to foster analysis of key issues including: pricing and reimbursement; marketing and advertising; intellectual property protection; FDA regulatory reform with respect to data exclusivity, biosimilars approval processes and safety; healthcare benefit design; new product R&D; and various healthcare system reform proposals. In addition, Dr. Manning was a Director in the Advisory Strategy Group at PricewaterhouseCoopers specializing in strategic partnerships, merger and acquisitions activity, and empirical economic analysis for several biopharmaceutical, financial, and healthcare clients.
Dr. Manning was an economics professor at Brigham Young University and a visiting professor in the Graduate School of Business at the University of Chicago. As an academic, his teaching and research focused on price theory, the economic analysis of law, industrial organization, and the economics of government regulation.
- In Merix Pharmaceutical Corp. v. Clinical Supplies Management, Inc. (CSM), retained as testifying expert on behalf of CSM in connection with alleged fraud and breach of contract claims related to the performance of a clinical trial for an over-the-counter medication. Authored expert report and provided deposition testimony that assessed damages assertions made by plaintiff’s experts. Judge Matthew F. Kennelly, of the US District Court for the Northern District of Illinois Eastern Division, granted summary judgment on a number of Merix’s damages claims. A jury ultimately found in CSM’s favor at trial.
- Authored an expert report and testified in National Union Fire Insurance Company of Pittsburgh, Pennsylvania v. Tyco Integrated Security, LLC on behalf of Tyco regarding damages arising from a theft of prescription drugs from a pharmaceutical company warehouse. In April 2016, a Florida federal jury found in Tyco’s favor, finding the security company not liable in the insurer’s negligence suit.
- Authored an expert report and provided deposition testimony in a breach of contract action on behalf of a pharmaceutical company asserting that a marketing partner had failed to perform its duties in a commercially reasonable manner.
Retained as expert on a breach of contract case between a pharmaceutical company and a contract manufacturer.
- Served as consultant to a university assessing damages against a consumer products company by an unauthorized filing of patents on property owned by the university. Submitted a declaration to a federal district court addressing recommended economic principles and methodologies for assessing the university’s intellectual property market value.
- Conducted detailed economic analysis on behalf of Eli Lilly in connection with its $5.4 billion acquisition of Novartis Animal Health. Both firms were active in developing and marketing animal health products, including medications used to treat pets and livestock. Bates White assessed overlaps in several areas, and presented results of its analysis to the FTC. The FTC approved the merger after an eight month investigation, with divestiture required in one product area, canine parasiticides.
- Retained as consulting expert by a class of state Medicaid claimants to evaluate the state’s application of an econometric model for benefit determination decisions.
Retained by a leading healthcare company to prepare a report analyzing the economics of the market for blood plasma products in response to changing demand and cost conditions.
Retained by a multinational life sciences company to analyze the market for oncology products with respect to the sustainability of current and projected future trends in pricing, utilization, and reimbursement.
PhD, Economics, University of Chicago
MA, Economics, University of Chicago
BA, Economics, Brigham Young University
- Law360, September 28, 2016
- International Journal of the Economics of Business, July 2016
- Risk-based Decision Making and Ethical Considerations in Donor Compensation for Plasma-derived Medicinal ProductsTransfusion, September 2016
- Tax Inversions: A Preliminary Review of Company Financial Data and Tax Inversions: How do Financial Metrics of Foreign Acquisitions Compare?April 6, 2016
- July 2015
- International Journal of the Economics of Business, June 2015
- Arlington, VA, October 7, 2016
- Washington, DC, April 20, 2016
- Luncheon Panel: Anti-Kickback StatuteJune 8, 2015
- Hilton Head, SC, May 28–29, 2015
- Arlington, VA, March 26–27, 2015
- Part of Bates White’s Life Sciences SymposiumJune 12, 2014
- March 2013
- San Francisco, CA, December 4, 2012 – December 5, 2012
- Christopher Stomberg and Richard Manning speak at McGuireWoods’ 4th Annual Medical Device and Life Sciences ConferenceChicago, IL, November 8, 2012
- Washington, DC, July 26, 2012
- Arlington, VA, May 3, 2012